Sheba Pediatric CAR-T Program for Multiple Myeloma at JCI accreditated and Top-10 Hospitals 2025 by Newsweek Hospital

• Terapia con cellule CAR-T
• Elettrocardiogramma (ECG)
• Esami del sangue
• Radiografia del torace
• Test anti-HIV
• Test Anti-HBC
• Test Anti-HCVAb
• Ecocardiografia
• Emocromo completo (CBC)
• Esame di biochimica del sangue
• PET/TC
• Consultazione con un oncologo
• Consultazione con un ematologo
• Consultazione con un immunologo
• Consultazione con un cardiologo
• Consultazione con un ematologo pediatrico
• Consultazione con un pediatra
• Consultazione con un oncoematologo
• Risonanza magnetica della testa
• Biopsia
• Emocromo completo con marcatori tumorali e proteinogramma

• 21 giorni in ospedale

• Trasferimento aeroporto-clinica-aeroporto

Sheba Pediatric CAR-T Program for Multiple Myeloma

At Sheba Medical Center, children and young patients with multiple myeloma have access to one of the most advanced and trusted CAR-T therapy programs in the world. While multiple myeloma is more common in adults, Sheba provides highly specialized care for young and complex cases, including relapsed or treatment-resistant disease.

A Personalized Treatment Designed for Each Patient

CAR-T therapy uses the patient’s own immune system to recognize and destroy cancer cells. For patients with multiple myeloma, this innovative approach offers a highly targeted option when standard treatments are no longer effective.

At Sheba, the entire CAR-T process is performed on-site, ensuring speed, precision, and optimal cell quality:

Apheresis – collection of the patient’s T-cells
Cell Engineering – genetic modification at Sheba’s Advanced Biotherapy Center
Infusion – reintroduction of modified cells to target myeloma cells

Because no steps are outsourced, treatment can begin quickly and is typically completed within ~10 days. CAR-T functions as a “living therapy,” continuing to work in the body and offering the potential for long-term disease control and remission.

Expert Pediatric Leadership and Care

The program is led by Prof. Amos Toren, a globally recognized expert in pediatric hemato-oncology and cellular therapies, with decades of experience and over 1,500 bone marrow transplants performed.

Patients are treated within a highly specialized environment that includes:

Dedicated pediatric and young adult CAR-T units with 24/7 monitoring
A multidisciplinary team of hemato-oncologists, immunologists, and supportive care specialists
A patient- and family-centered approach, ensuring comfort and continuous support
Full international patient services, including travel and care coordination
Advanced Expertise in Complex Cases

Sheba is a global leader in CAR-T therapy, with strong clinical outcomes across hematologic cancers:

~90% remission in pediatric patients
~80% in young adults (up to 23 years)
~70% in adults

The program is experienced in managing rare, complex, and high-risk myeloma cases, offering advanced treatment options when other therapies have been exhausted.

Comprehensive Evaluation and Ongoing Support

Each patient undergoes a detailed diagnostic evaluation, including:
advanced imaging, bone marrow testing, genetic and molecular profiling, and full cardiac and pulmonary assessment.

Care is provided in English, Russian, and Arabic, ensuring clear communication and a supportive experience for international families.

A Trusted Place for Advanced Care

By combining cutting-edge science, rapid access to therapy, and compassionate care, Sheba offers one of the most advanced CAR-T programs for multiple myeloma focused on improving outcomes and helping patients return to a better quality of life.

• Coordinatore medico personale
• Organizzazione dei viaggi medici — prenotazione di biglietti aerei e camere d'albergo a prezzi speciali per i partner
• Tutela degli interessi dei pazienti durante il viaggio medico